Mizuho analyst Vikram Malhotra downgraded Sabra Health Care (SBRA) to Neutral from Outperform with an unchanged price target of $20. The firm says multiples in the skilled nursing facility group “reflect a perfect set-up amid higher regulatory risk.” From being outright positive on the group, Mizuho is now neutral.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: